Greenalia S.A. has been nominated by BME in the “Star 2018” category in the “Small and Mid Cap Awards 2018”. This nomination took place as part of the 8thMAB Meeting and MEDCAP Forum, held on May 29, 30 and 31 at the Madrid Stock Exchange. This selection means for Greenalia its consolidation as a reference company in the alternative stock market, where it has been listed since December 1st.
This award was presented by Jesus González Nieto, Managing Director of the MaB to Antonio Fernández-Montells (CFO of Greenalia). Each year the EUROPEAN ISSUERS and FESE announce these awards and the European Stock Exchanges present their candidates in the different categories. After a selection of the national nominees, there will be three finalists per category who will be invited in November to the award ceremony in Brussels where the winner will be chosen for each category.
The “Star 2018” category rewards the company with exceptional performance in its sector with clear growth potential. This award also considers the well-management as well as the destination of the funds obtained in the IPO process.
Greenalia began its journey in the alternative stock market (MAB) on December 1st. Since then, its shares haveraised up to 49.75% (over 20% in 2018), reaching a current capitalization of 65 million euros.
2017 closing and business plan forecasts:
The company presented the 2017 fiscal year results last April; as well as the annual accounts audited by PwC (both documents can be found on the BME-MAB website). Greenalia achieved the objectives set out in its business plan for 2017, exceeding the 35 million of consolidated turnover and reaching an EBITDA of 1.9 million euros (an increase of 101% compared to the previous year), confirming the growth and complying with the estimated budget.